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Abstract
We implemented a guideline for appropriate acid suppressant use in hematology-oncology 
patients. This intervention resulted in a sustained reduction in proton pump inhibitor (PPI) use 
without an increase in rates of gastrointestinal bleeding. Practice guidelines are effective in 
reducing PPI use, which is associated with risk of Clostridioides difficile infection.
INTRODUCTION
Clostridioides difficile is a common cause of healthcare-associated infections in patients 
with hematologic malignancy1. Proton-pump inhibitor (PPI) use has been associated with a 
significantly increased risk of C. difficile infection (CDI)2,3. At our institution, 40% of 
hematology-oncology patients with a positive C. difficile test received a PPI in the prior 72 
hours4. We implemented a guideline for appropriate PPI use in our hematology-oncology 
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units and evaluated its impact on rates of PPI administration and gastrointestinal (GI) 
bleeding.
METHODS
This study was conducted on three inpatient hematology-oncology units at the Hospital of 
the University of Pennsylvania, a 791-bed tertiary care medical center. The study guideline 
(Figure 1) was implemented on November 13, 2017 (See Supplementary Methods). We 
analyzed the impact of this intervention, comparing a 14-month baseline cohort (September 
2016–October 2017) prior to implementation of the guideline to the 10-month intervention 
cohort (November 2017–August 2018) after implementation.
Our primary outcome of interest was rate of PPI use measured in days of therapy (DOT). We 
also ascertained rates of histamine-2 receptor antagonist (H2RA) administration and C. 
difficile positive tests4. Medical record review was performed in a subset of patients with 
medication orders for PPIs, comparing a 3-month period before (August 12, 2017 to 
November 12, 2017) and after the intervention (November 13, 2017 to February 13, 2018). 
Data that were collected included PPI indication (determined by review of clinical 
documentation), acid suppressant prescription prior to admission, symptomatic or 
endoscopic evidence of GI bleeding, and PPI continuation on discharge. This study was 
approved by the University of Pennsylvania Institutional Review Board. Statistical methods 
are described in the Supplementary Methods.
RESULTS
Compared to the baseline time period, there was a significant reduction in PPI use on the 
study units during the intervention period, from a mean of 1092.8 DOT/month (SD 113.5) to 
a mean of 752.4 DOT/month (SD 73.2) (P<0.001). This decline in PPI administration was 
sustained over the intervention period, with 661 DOT in the last month of the intervention, 
which represented a 48% decline from the peak of use in October 2016 (1275 DOT). Using 
segmented regression analysis, there was a significant immediate reduction with the 
intervention of 195.5 DOT (95% confidence interval [CI], reduction of 87.8 – 303.2; 
P=0.001) (Figure 2). Additionally, there was a significant post-intervention linear trend of a 
reduction in PPI administration of 18.2 DOT per month (95% CI reduction of 11.2 – 25.1; 
P<0.001). Assessing rate of PPI administration per 1000 patient days, model fit, change in y-
intercept, and the post-intervention linear trend remained significant (Supplementary Table 
1).
H2RA use increased from an average of 615.1 DOT (SD 124.1) in the baseline group 
compared to 714.1 DOT (SD 88.8) in the intervention group (P=0.04). Using segmented 
regression analysis, there was no immediate change after guideline introduction (reduction 
of 102.9 DOT (95% CI reduction of 247.6 – increase of 41.7); P=0.15). However, we found 
a significant post-intervention linear trend of an increase in H2RA use of 19.1 DOT per 
month (95% CI increase of 5.1 – 33.0; P=0.01). Assessing rate of H2RA administration per 
1000 patient days, there was no significant change in either the immediate post-intervention 
change or linear trend.
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In medical record review of a subset of patients, there were 155 PPI medication orders in the 
baseline cohort and 126 in the intervention cohort (Supplementary Table 2). Of these, the 
majority represented continuation of a prior-to-admission medication; only 43 (28%) in the 
baseline and 23 (18%) in the intervention group were new orders (P=0.047). There was no 
difference in the order indication across time periods. An increased proportion of PPIs were 
continued on discharge in the intervention group compared to the baseline group (85% vs 
70%, P=0.004). The majority of these represented continuation of a prior-to-admission 
medication (94/106 in the baseline group and 95/107 in the intervention group).
Rates of GI bleeding in this subset of patients were low, 6 (3.9%) in the baseline group 
compared to 6 (4.8%) in the intervention group (P=0.75). There were no significant 
differences in other secondary outcomes between the groups (Supplementary Table 3).
There was no significant change in rates of C.difficile positive tests on study units, with an 
average of 2.057/1000 patient days (SD 1.289) in the baseline group and 2.046/1000 patient 
days (SD 0.959) in the intervention group (P=0.93). However, the study was not powered to 
determine an impact of our intervention on rates of C.difficile.
DISCUSSION
We evaluated the impact of implementation of a multidisciplinary guideline for appropriate 
acid suppression in our hematology-oncology population. Our results were notable for 
several findings. First, we demonstrated a large and sustained decline in PPI administration 
with guideline implementation. Second, while not statistically significant, there was a trend 
towards decreased inappropriate ordering for GI bleeding prophylaxis during chemotherapy. 
Finally, there was no increase in rates of GI bleeding, indicating low risk of harm with our 
intervention.
In a population with high rates of colonization and infection with C. difficile,1–3 it is 
important to reduce unnecessary exposures that increase the risk of CDI. Implementation of 
our guideline resulted in an average 31% reduction in PPI use over time, with a sustained 
decline over the study period. Prior studies have investigated various methods of reducing 
PPI utilization in general medical patients, including a pharmacist-led inpatient PPI 
stewardship team5 and computerized order entry alerts with prospective audit and feedback6. 
These interventions have demonstrated similar levels of success with approximately 41% 
and 37% reductions, respectively. Our study focused on patients with hematologic 
malignancy and addressed acid suppressant guidelines unique to this population, 
prophylactic acid suppressant use, and symptomatic management during chemotherapy. We 
believe that addressing these areas of frequent, often inappropriate, utilization of acid 
suppressants in this patient population contributed to the success of our intervention without 
the need for prospective audit and feedback.
While we noted a decrease in rates of PPI use, our intervention may have resulted in 
increased utilization of H2RAs. However, after adjusting for patient days on study units, 
there was no significant increase in H2RA use. Additionally, while H2RA agents have also 
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been associated with risk of CDI, they carry a 29% lower odds of CDI when compared to 
PPIs7,8.
There was no increased rate of GI bleeding with our intervention. This is consistent with 
previous studies that have shown that serious adverse events such as requirement for blood 
transfusion is uncommon after chemotherapy9. Additionally, rates of GI bleeding with 
systemic corticosteroid use has been found to be similar to placebo in meta-analysis10.
Our study has potential limitations. First, we utilized a quasi-experimental design, which 
may be biased by confounding variables that impacted PPI prescribing. However, there were 
no additional interventions focused on PPI prescribing during the study period. Second, this 
study was one of multiple ongoing interventions targeted towards reducing C. difficile rates, 
and was not powered to detect a significant change in this outcome. Additionally, our study 
focused on hematology-oncology patients at an academic institution and may not be 
generalizable to dissimilar populations. Finally, high rates of orders with unclear indications 
and continuation on discharge in the intervention group suggests opportunity for additional 
improvement.
In conclusion, our findings highlight the impact of a multidisciplinary practice guideline in 
effectively reducing PPI use in hospitalized patients with hematologic malignancy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Guideline for acid suppression in hematology-oncology patients NOTE. Chemo, 
chemotherapy; NSAIDs, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitor; 
H2RA, histamine-2 receptor antagonist; CrCl, creatinine clearance; GI, gastrointestinal
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Figure 2. 
Segmented regression analysis of monthly proton pump inhibitor administration on three 
hematology-oncology units NOTE. PPI, proton pump inhibitor
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